Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals
Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
MBK
0.00%
75.0¢
Mooroolbark & District Financial Services Limited
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MBK | Ann:Company Delisting - Friday, 10th of May 2019. | 18/04/19 | 0 | 611 | |||
|
|||||||
MBK | Ann:Final Director's Interests - Joan Drew | 20/03/19 | 0 | 658 | |||
|
|||||||
MBK | Ann:Resignation of Director - Joan Drew | 15/03/19 | 0 | 837 | |||
|
|||||||
MBK | Ann:Half Yearly Financial Statements - 31 December 2018 (Price Sensitive) | 14/03/19 | 0 | 770 | |||
|
|||||||
MBK | Ann:Results and Minutes of 2018 AGM | 07/12/18 | 0 | 1.0K | |||
|
|||||||
MBK | Ann:Dividend Notification | 25/10/18 | 0 | 975 | |||
|
|||||||
MBK | Ann:Annual Report - 30 June 2018 (Price Sensitive) | 16/10/18 | 0 | 976 | |||
|
|||||||
MBK | Ann:Notice of 2018 Annual General Meeting | 10/10/18 | 0 | 988 | |||
|
See All Discussions